Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2019

Feb 14, 2020

SELL
$86.8 - $118.57 $945,252 - $1.29 Million
-10,890 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$83.82 - $101.5 $912,799 - $1.11 Million
10,890 New
10,890 $979,000
Q4 2018

Feb 14, 2019

SELL
$68.32 - $124.36 $455,831 - $829,729
-6,672 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$98.88 - $125.85 $659,727 - $839,671
6,672 New
6,672 $822,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $13B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Maven Securities LTD Portfolio

Follow Maven Securities LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Maven Securities LTD, based on Form 13F filings with the SEC.

News

Stay updated on Maven Securities LTD with notifications on news.